Patents by Inventor Catherine Haluszczak

Catherine Haluszczak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD40 AGONIST ANTIBODY /TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY
    Publication number: 20200087370
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Application
    Filed: June 24, 2019
    Publication date: March 19, 2020
    Inventors: Ross KEDL, Phillip J. Sanchez, Catherine Haluszczak
  • Nucleic acid construct encoding an agonistic anti-CD40 antibody and a type I interferon
    Patent number: 10329338
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: June 25, 2019
    Assignee: The Regents of the University of Colorado
    Inventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
  • CD40 Agonist Antibody /Type 1 Interferon Synergistic Adjuvant Combination, Conjugates Containing and Use Thereof as a Therapeutic to Enhance Cellular Immunity
    Publication number: 20150376253
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Application
    Filed: July 1, 2015
    Publication date: December 31, 2015
    Inventors: Ross KEDL, Phillip J. Sanchez, Catherine Haluszczak
  • Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
    Patent number: 9095608
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Grant
    Filed: February 16, 2012
    Date of Patent: August 4, 2015
    Assignee: The Regents of the University of Colorado
    Inventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
  • Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
    Patent number: 8361471
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: January 29, 2013
    Assignee: The Regents of the University of Colorado
    Inventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
  • CD40 AGONIST ANTIBODY /TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY
    Publication number: 20120251494
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Application
    Filed: February 16, 2012
    Publication date: October 4, 2012
    Inventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
  • Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
    Patent number: 8137672
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: March 20, 2012
    Assignee: The Regents of the University of Colorado
    Inventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
  • CD40 AGONIST ANTIBODY /TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY
    Publication number: 20110286968
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Application
    Filed: June 21, 2011
    Publication date: November 24, 2011
    Inventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
  • Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
    Patent number: 7993648
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Grant
    Filed: May 3, 2007
    Date of Patent: August 9, 2011
    Assignee: The Regents of the Universitry of Colorado
    Inventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
  • CD40 AGONIST ANTIBODY/TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY
    Publication number: 20100317111
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Application
    Filed: July 29, 2010
    Publication date: December 16, 2010
    Inventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
  • CD40 AGONIST ANTIBODY /TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY
    Publication number: 20080050340
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylacetic and therapeutic) is also provided.
    Type: Application
    Filed: May 3, 2007
    Publication date: February 28, 2008
    Applicant: REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Ross Kedl, Phillip Sanchez, Catherine Haluszczak